suit-in-crowd
19 February 2014Big Pharma

SPCs: a call for clarity

Supplementary protection certificates (SPCs) are national rights in Europe that extend patent protection for medicinal and plant protection products. Their aim is to compensate patentees for the years of patent term lost during lengthy regulatory approval processes that are necessary to get such products to market. Given that up to five-and-a-half years of additional protection can be gained beyond patent expiry, SPCs are often hard fought over before patent offices and the courts.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
26 October 2017   Patent applicants have long wrestled with the question of how much experimental evidence to include in a new patent application. David Carling and Richard Wells of Potter Clarkson examine the issue in Europe.

More on this story

Big Pharma
26 October 2017   Patent applicants have long wrestled with the question of how much experimental evidence to include in a new patent application. David Carling and Richard Wells of Potter Clarkson examine the issue in Europe.

More on this story

Big Pharma
26 October 2017   Patent applicants have long wrestled with the question of how much experimental evidence to include in a new patent application. David Carling and Richard Wells of Potter Clarkson examine the issue in Europe.